Literature DB >> 33522740

Metabolic and Toxic Myelopathies.

Natalie Elizabeth Parks.   

Abstract

PURPOSE OF REVIEW: This article describes the clinical presentation, relevant diagnostic investigations, and treatment of metabolic and toxic myelopathies. RECENT
FINDINGS: Metabolic myelopathies, including those due to deficiency of vitamin B12, folate, copper, or vitamin E, are preventable and typically respond to supplementation. In metabolic myelopathy, early recognition and treatment are important to reduce morbidity, particularly due to subacute combined degeneration of the spinal cord. Toxic myelopathies, including those due to medical interventions (eg, methotrexate, radiation), dietary toxins (eg, lathyrism, konzo), and drugs of abuse (eg, heroin), typically result in permanent neurologic deficits. Toxic myelopathy due to hepatic dysfunction may be reversible if patients receive early intervention, whereas nitrous oxide myelopathy responds to vitamin B12 replacement and cessation of exposure. In toxic myelopathy, it is best to avoid the provoking factor when possible or attempt to mitigate risk by identifying risk factors for developing myelopathy.
SUMMARY: Metabolic and toxic myelopathies are important causes of morbidity that require a high index of suspicion for diagnosis.
Copyright © 2021 American Academy of Neurology.

Entities:  

Year:  2021        PMID: 33522740     DOI: 10.1212/CON.0000000000000963

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  2 in total

1.  Clinical Presentation of Subacute Combined Degeneration in a Patient With Chronic B12 Deficiency.

Authors:  Nathan Kostick; Evan Chen; Tabitha Eckert; Igor Sirotkin; Esther Baldinger; Alfred Frontera
Journal:  Fed Pract       Date:  2022-03-14

Review 2.  Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing.

Authors:  Michlene Passeri; Elizabeth Matthews; Ryan Kammeyer; Amanda L Piquet
Journal:  Front Neurol       Date:  2022-07-28       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.